Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-74,000
Closed -$19.3M 166
2024
Q4
$19.3M Sell
74,000
-72,000
-49% -$21.4M 2.62% 6
2024
Q3
$47M Buy
146,000
+145,400
+24,233% +$47.6M 6.56% 2
2024
Q2
$18.7M Sell
600
-59,400
-99% -$17.5M 3.27% 7
2024
Q1
$17.1M Buy
60,000
+25,000
+71% +$7.32M 1.87% 14
2023
Q4
$10.1M Buy
+35,000
New +$9.54M 0.94% 34
2022
Q3
Sell
-100,000
Closed -$24.3M 108
2022
Q2
$24.3M Hold
100,000
4.44% 3
2022
Q1
$24.2M Buy
+100,000
New +$23M 3.18% 4

Other funds holding AMGN

Ikarian Capital's AMGN Position: Q1 2026 in Review

Ikarian Capital sold out of Amgen (AMGN) in Q1 2026, closing a stake of 45,000 shares — an estimated $14.7M sold.

Ikarian Capital first reported a position in AMGN in Q1 2022 and held it in 4 quarters. The position peaked at $14.7M in Q4 2025. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Ikarian Capital reported no remaining Amgen position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 45,000 Amgen shares in Q1 2026, an estimated $14.7M.
  • Ikarian Capital first reported a position in Amgen in Q1 2022 and held it in 4 quarters.
  • Ikarian Capital's Amgen position peaked at $14.7M in Q4 2025.
  • 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.